-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On June 21, Guangyuyuan issued an announcement on the change of executiv.
The board of directors recently received written resignation reports from the company's vice presidents Zhang Yi and Liang Pe.
Both of them resigned as vice presidents for personal reaso.
After resigning, they no longer hold any positions in the compa.
The company stated that the resignation of the two will not adversely affect the company's daily operation and management activiti.
The announcement also shows that in view of the recent resignation of .
Zhang Bin as chairman of Shanxi Guangyuyuan, according to relevant regulations, Shanxi Guangyuyuan needs to change its legal representative to the current chairman, .
Lv Hong.
Since the beginning of this year, Guangyuyuan's executives have changed frequent.
For example, on April 11, Guangyuyuan announced that Shi Jing, an employee supervisor of the seventh board of supervisors, no longer served as an employee representative supervisor due to work reasons, and the company elected Li Na as an employee representative supervisor of the seventh board of supervisors; April 27 , the company's independent director Wang Binquan came to the news of his official resignation; on May 10, 2022, Guangyuyuan announced that Kang Yun resigned from the company's securities affairs representative position for personal reasons, and would no longer hold any position in the company after resignation; then in May On the 19th, Guang Yuyuan also announced that the board of directors of the company recently received a written resignation report from Fu Shuhong, the vice president of the compa.
It is worth mentioning that as early as February, Fu Shuhong applied to resign as the company's chief financial officer due to job chang.
From the perspective of the reasons for the resignation of company executives, the main reasons are personal reasons, followed by work reaso.
The industry believes that changes in executives of pharmaceutical companies are usually related to corporate restructuring and performan.
According to the data, Guangyuyuan is mainly engaged in the production and sales of traditional Chinese medicine produc.
According to different product positioning and sales channels, the company's pharmaceutical industry mainly includes three major sectors: traditional Chinese medicine, high-quality traditional Chinese medicine and health wi.
Angong Niuhuang Pill, Niuhuang Qingxin Pill and more than 100 kinds of traditional Chinese medicine approval number
In 2021, Guangyuyuan achieved operating income of 854 million yuan, a year-on-year decrease of 23%; realized a net profit of -316 million yuan attributable to the parent, compared with 3003 million yuan in the same period last year, failing to maintain a profitable sta.
Recently, the company has attracted the attention of the Shanghai Stock Exchange due to a surge in sales expenses in 202The Shanghai Stock Exchange pointed out in the question that Guangyuyuan's sales expenses in 2021 will be 782 million yuan, an increase of 546 million yuan compared with the 2021 semi-annual report, and a year-on-year increase of 329% in the case of a 23% year-on-year decline in annual operating inco.
The annual sales expense ratio was 957%, a year-on-year increase of 392 percentage points, much higher than the average level of the traditional Chinese medicine industry, while the company's sales staff remained unchanged year-on-ye.
The Shanghai Stock Exchange asked Guangyuyuan to explain the reason and rationality of the inconsistency between sales expenses and revenue changes, and whether there was any disguised transfer of benefi.
In this regard, Guangyuyuan replied that the sales expenses in 2021 will be 782189 million yuan, of which marketing expenses and advertising expenses account for 865% of the sales expens.
The company stated that in order to cope with the adverse effects of the epidemic, national medical insurance control fees, and prescription drug supervision, the company has increased terminal marketing investment and dynamic sales efforts; in addition, the terminal volume will increase in 2021, and the digestion of channel inventory has achieved certain results, but at the same time the company has achieved certain resul.
The increased investment in marketing promotion has also led to an increase in sales expenses; the company's collaborative distribution marketing model leads to a direct impact on the terminal pure sales volume of the company's promotion expenses; in order to promote the rapid recovery of accounts receivable, the company further strengthens terminal dynamic sal.
The above reasons combined lead to an increase in the company's sales expenses when the company's operating income declined during the reporting period, and the sales expenses were inconsistent with the direction of changes in operating inco.
In the secondary market, on June 22, Guangyuyuan rose sharply in the early trading, with an intraday increase of
As of 13:40, it was reported at 36 yuan, with a turnover of 456 million yuan and a turnover rate of 9
Click to enter the exhibition
The board of directors recently received written resignation reports from the company's vice presidents Zhang Yi and Liang Pe.
Both of them resigned as vice presidents for personal reaso.
After resigning, they no longer hold any positions in the compa.
The company stated that the resignation of the two will not adversely affect the company's daily operation and management activiti.
The announcement also shows that in view of the recent resignation of .
Zhang Bin as chairman of Shanxi Guangyuyuan, according to relevant regulations, Shanxi Guangyuyuan needs to change its legal representative to the current chairman, .
Lv Hong.
Since the beginning of this year, Guangyuyuan's executives have changed frequent.
For example, on April 11, Guangyuyuan announced that Shi Jing, an employee supervisor of the seventh board of supervisors, no longer served as an employee representative supervisor due to work reasons, and the company elected Li Na as an employee representative supervisor of the seventh board of supervisors; April 27 , the company's independent director Wang Binquan came to the news of his official resignation; on May 10, 2022, Guangyuyuan announced that Kang Yun resigned from the company's securities affairs representative position for personal reasons, and would no longer hold any position in the company after resignation; then in May On the 19th, Guang Yuyuan also announced that the board of directors of the company recently received a written resignation report from Fu Shuhong, the vice president of the compa.
It is worth mentioning that as early as February, Fu Shuhong applied to resign as the company's chief financial officer due to job chang.
From the perspective of the reasons for the resignation of company executives, the main reasons are personal reasons, followed by work reaso.
The industry believes that changes in executives of pharmaceutical companies are usually related to corporate restructuring and performan.
According to the data, Guangyuyuan is mainly engaged in the production and sales of traditional Chinese medicine produc.
According to different product positioning and sales channels, the company's pharmaceutical industry mainly includes three major sectors: traditional Chinese medicine, high-quality traditional Chinese medicine and health wi.
Angong Niuhuang Pill, Niuhuang Qingxin Pill and more than 100 kinds of traditional Chinese medicine approval number
In 2021, Guangyuyuan achieved operating income of 854 million yuan, a year-on-year decrease of 23%; realized a net profit of -316 million yuan attributable to the parent, compared with 3003 million yuan in the same period last year, failing to maintain a profitable sta.
Recently, the company has attracted the attention of the Shanghai Stock Exchange due to a surge in sales expenses in 202The Shanghai Stock Exchange pointed out in the question that Guangyuyuan's sales expenses in 2021 will be 782 million yuan, an increase of 546 million yuan compared with the 2021 semi-annual report, and a year-on-year increase of 329% in the case of a 23% year-on-year decline in annual operating inco.
The annual sales expense ratio was 957%, a year-on-year increase of 392 percentage points, much higher than the average level of the traditional Chinese medicine industry, while the company's sales staff remained unchanged year-on-ye.
The Shanghai Stock Exchange asked Guangyuyuan to explain the reason and rationality of the inconsistency between sales expenses and revenue changes, and whether there was any disguised transfer of benefi.
In this regard, Guangyuyuan replied that the sales expenses in 2021 will be 782189 million yuan, of which marketing expenses and advertising expenses account for 865% of the sales expens.
The company stated that in order to cope with the adverse effects of the epidemic, national medical insurance control fees, and prescription drug supervision, the company has increased terminal marketing investment and dynamic sales efforts; in addition, the terminal volume will increase in 2021, and the digestion of channel inventory has achieved certain results, but at the same time the company has achieved certain resul.
The increased investment in marketing promotion has also led to an increase in sales expenses; the company's collaborative distribution marketing model leads to a direct impact on the terminal pure sales volume of the company's promotion expenses; in order to promote the rapid recovery of accounts receivable, the company further strengthens terminal dynamic sal.
The above reasons combined lead to an increase in the company's sales expenses when the company's operating income declined during the reporting period, and the sales expenses were inconsistent with the direction of changes in operating inco.
In the secondary market, on June 22, Guangyuyuan rose sharply in the early trading, with an intraday increase of
As of 13:40, it was reported at 36 yuan, with a turnover of 456 million yuan and a turnover rate of 9
Click to enter the exhibition
